News – Page 1149 – Endpoints News

Medigene spins out AAV tech to a new biotech upstart in Sweden

9 years ago

Biotech backer Versant arms itself with record $400M fund, targets a new wave of upstarts

9 years ago

Chinese VC syndicates wager $172M on Ascentage and Ascletis, flagging a new trend

9 years ago

Inotek starts off 2017 with a PhIII failure for lead drug, shares crater

9 years ago

Jounce rings out the old year with a $75M IPO bid for the New Year

9 years ago

Pfizer partner Opko reports a PhIII failure for growth hormone, but tries to steer out of a crash

9 years ago

In back-to-back disasters, the FDA spurns Innocoll’s NDA and shares plunge (again)

9 years ago

New drug price controversy looms as Biogen stuns payers with Spinraza's $750K sticker — analyst

9 years ago

Provectus boots its interim CEO following expense probe, 10 months after founder left under the same cloud

9 years ago

Faced with a dilemma, the FDA rejects Cempra's antibiotic, demands big safety study

9 years ago

In back-to-back failures, Anthera’s CF drug Sollpura falls short in PhIII, shares crater (again)

9 years ago

Seattle Genetics stock tumbles after 4 deaths force the FDA to slap a clinical hold on AML drug

9 years ago

Biogen, Ionis win FDA OK for spinal muscular atrophy drug Spinraza

9 years ago

Merck’s Ebola vaccine promises to stop the next outbreak in its tracks

9 years ago

Bial accused of negligence in lethal drug trial — Nature

9 years ago

Make that two biotech reverse mergers in one day

9 years ago

WSJ's editorial page puts the blame over Exondys 51 controversy on insurers, regulators and reporters

9 years ago

ChemoCentryx grabs $50M upfront, adds development partnership with Vifor

9 years ago

The Senate fumbles its first stab at pharma profiteering, keeping the issue front and center in 2017

9 years ago

Struggling OvaScience reorganizes, stock plunges; Chugai inks €130M deal; Ironwood, Allergan report new linaclotide ...

9 years ago

Crushed by a trial failure, Tokai hands the reins — and the stock listing — to Otic

9 years ago

The Senate dissects Martin Shkreli's scheme to grab a $1B windfall

9 years ago

Roche readies a hunt for marketing OK on hemophilia blockbuster hopeful emicizumab after PhIII success

9 years ago

Alexion adds a failed pivotal Soliris trial to an air of crisis. The perfect time to talk buyout

9 years ago

First page Previous page 1146 1147 114811491150 1151 1152 Next page Last page